Who funds this research project?

This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the JTI-CP-IMI funding scheme.

What is the EU contribution?

The European Commission contributes €11.0M toward a total project budget of €28.6M.

Which EU programme funds it?

The project is funded under Seventh Framework Programme (2007–2013).

Who coordinates the project?

The project is coordinated by THE EUROPEAN MEDICINES AGENCY (NL).

What is the project timeline?

The project runs from 2009-09-01 to 2015-04-30 — approximately 5.7 years.

Where can I find the full project record?

The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 115004.

CORDIS · 115004 · FP7

PROTECT Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium

Coordinator: THE EUROPEAN MEDICINES AGENCY (NL)

Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Agency (EMEA), willdevelop and test methods of proactive monitoring of drug safety and benefit risk (B/R) assessment utilising a large range of EU data sources and expertise. in partnership with EFP1A c…

EU contribution

€11.0M

Total cost

€28.6M

Period

2009-09-01 → 2015-04-30

Framework

Seventh Framework Programme (2007–2013)

Funding scheme

JTI-CP-IMI

Status

SIGNED

About Seventh Framework Programme (2007–2013)

The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.

Co-funding: the European Union contributes €11.0M toward a total project budget of €28.6M — a funding rate of 38%, with the remainder covered by the consortium partners. The project runs over approximately 5.7 years from 2009-09-01 to 2015-04-30.

Full record on CORDIS — partners, deliverables, publications, news.

Open on cordis.europa.eu →

More from NL

see all →

Other FP7 projects

see all →

Frequently asked questions

Who funds this research project?: This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the JTI-CP-IMI funding scheme.
What is the EU contribution?: The European Commission contributes €11.0M toward a total project budget of €28.6M.
Which EU programme funds it?: The project is funded under Seventh Framework Programme (2007–2013).
Who coordinates the project?: The project is coordinated by THE EUROPEAN MEDICINES AGENCY (NL).
What is the project timeline?: The project runs from 2009-09-01 to 2015-04-30 — approximately 5.7 years.
Where can I find the full project record?: The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 115004.

Source: CORDIS · 115004